Breaking: GLP-1 Prices Slashed Nationwide — But Are They Finally Affordable? скачать в хорошем качестве

Breaking: GLP-1 Prices Slashed Nationwide — But Are They Finally Affordable?

📍 LIVE from Obesity Week in Atlanta, Georgia — The White House has just announced a major step forward for affordability and access to GLP-1 medications. Under new agreements with Eli Lilly and Novo Nordisk, the prices of Ozempic, Wegovy, Mounjaro, and Zepbound will drop dramatically — and, for the first time ever, Medicare will cover obesity medications beginning in 2026. 💊 Here’s what’s changing: Ozempic → $350/month (down from $1,000) Wegovy → $350/month (down from $1,350) Zepbound → $346/month (down from $1,086) Oral GLP-1s (like Wegovy pill or orforglipron) → $150/month Medicare & Medicaid price → $245/month Medicare copay → $50/month Eli Lilly is also cutting Zepbound prices by $50 right now on its direct platform, LillyDirect. This is an incredible step toward access and affordability, especially for seniors and Medicare patients who’ve been left out of treatment options — but it’s not the finish line. Many people, including us, still pay out of pocket, and hundreds of dollars a month is still not affordable for most Americans. This is progress. It’s hope. But the fight for fairness and true affordability continues. 💬 We’re not a political channel, but we cover politics where it intersects with GLP-1s and access to care. We’re excited to see progress on pricing — no matter which side of the aisle it comes from. Please be kind in the comments. We’re fighting the disease of obesity, not each other.